Shire in $30bn approach for Baxalta

Irish pharma company proposes deal after initial rebuff

Shire eyes big league with Baxalta bid

Completion of $30bn deal would push UK drugmaker up global ranks

Shire buys US eyecare business for $300m

Drugmaker bolsters move into ophthalmics with all-cash deal

GSK rehires suspected China whistleblower

Vivian Shi rejoins company almost 3 years after she was removed

Health experts hail Ebola breakthrough

Preliminary test results for vaccine show positive

©Charlie Bibby

Celgene hesitation costs it almost $7bn

Receptos deal could have been made for much less two years ago

US dollar pushes Sanofi profit higher

Sales rise 16%, buoyed by exchange rates and Genzyme biotech unit

AstraZeneca beats earnings expectations

Pharma group points to strong pipeline of cancer drugs

Papaver somniferum. Seed pod of Opium Poppy.

Pharmaceuticals: Prescribing pain

Increasing abuse of painkillers in the US is putting the industry under pressure to make the drugs tamper-proof

Wanted: Recreational drug users — will pay

Race is on to develop new ‘abuse-deterrent’ opioid painkillers

2016 earnings growth promise by ‘new GSK’

Leading UK drugmaker highlights R & D progress as sales advance 7%

Lone Star seeks to score at Wembley

Texan private equity group snaps up Quintain Estates for £700m

Pfizer chief has ‘courage’ to pursue deals

Speculation over plans for its $17bn cash pile has grown as rivals have consolidated

Clinical trial data should be made public

Drug companies and regulators are adopting transparency too slowly

France shrugs off the smoking ban

The country that gave us Gitanes may soon enact strict antismoking laws, writes Adam Thomson

Hikma boosts US generics with Roxane buy

Jordanian group to pay a mixture of cash and shares to Boehringer

Allergan paves way for new mega deal

Chief hints at ‘transformational’ purchase after generics sale

Pharma M&A: portfolio theory

Even after a $40bn deal, the pharma sector remains unsettled

Upbeat Reckitt raises growth forecasts

Dettol disinfectant maker reports 10% profit rise as outlook for Europe and North America stabilises

Mylan plunges after Teva abandons bid

Shares drop as Israeli group pursues rival Allergan deal

COMPANIES NEWS ON TWITTER

More FT Twitter accounts
SHARE THIS QUOTE